mAbDx monoclonal antibodies that recognize mtDNA-encoded OXPHOS proteins have been used in an Imaging Mass Cytometry study of inherited mitochondrial disease.

mAbDx collaborated on and provided novel monoclonal antibodies used in an Imaging Mass Spectrometry study entitled " A stagewise response to mitochondrial dysfunction in mitochondrial DNA maintenance disorders" that has been published in BBA - Molecular Basis of Disease (BBA - Molecular Basis of Disease 1870 (2024) 167131).

Imaging Mass Cytometry (IMC) allows simultaneous analysis of large number of protein targets in a single tissue section, while maintaining sufficient spatial resolution for single and sub-cellular analysis. This study characterized inherited mitochondrial Oxidative Phosphorylation (OXPHOS) deficiencies across all five OXPHOS complexes to better understand the response of muscle fibers to OXPHOS deficiency in patients with mtDNA maintenance disorders.

The study harnessed the power of Imaging Mass Cytometry to simultaneously probe 19 signaling proteins, four mitochondrial markers, and a muscle fiber marker. This allowed the examination of single fiber and sub-cellular levels and distribution of a range of key metabolic and signaling proteins. Combined OXPHOS Complex I and IV deficiencies were found to be the most common deficits. Interestingly, in fibers deficient for one or more OXPHOS complexes, the remaining complexes were often upregulated beyond the increase of mitochondrial mass typically observed in ragged red fibers. Further, OXPHOS deficient fibers exhibited an increase in the abundance of proteins involved in proteostasis, e.g. HSP60 and LONP1, and regulation of mitochondrial metabolism (including oxidative phosphorylation and proteolysis, e.g. PHB1). The analysis suggests that the cellular response to mitochondrial dysfunction changes depending on the combination of deficient oxidative phosphorylation complexes in each fiber.

Other articles

Novel monoclonal antibodies that recognize mtDNA-encoded OXPHOS proteins have been developed by mAbDx and used in an Imaging Mass Cytometry (IMC) study of Parkinson’s disease.

Tue 08 August 2023

mAbDx collaborated on and provided novel monoclonal antibodies used in an Imaging Mass Spectrometry study entitled "Parkinson’s disease neurons exhibit alterations in mitochondrial quality control proteins" that has been published in npj Parkinson’s Disease (2023)9:120.

Mitochondrial dysfunction has been suggested to contribute to Parkinson’s disease …
read more
Oregon Innovation Fund SBIR Matching Grant awarded to mAbDx

Thu 25 August 2022

The Oregon Business Development Department has awarded a $50,000 Oregon Innovation Fund SBIR Matching Grant (contract # C2022611) to mAbDx to support work on their SBIR funded project Simultaneous Diagnosis of Dengue and Prognosis of Severe Dengue with a Single Point-of-Care Test, NIAID grant number 1R43AI162484-01A1.

Dengue is the most …
read more
mAbDx, Inc. Awarded SBIR Phase I Grant

Wed 25 August 2021

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded mAbDx, Inc., a major Phase I SBIR grant ($599,913 for a 2-year study) to create a rapid Point of Care test with visual plus/minus readout that will not only diagnose Dengue infections early, but also be prognostic …
read more
The mAbDx Vibriosis RapidTest has been used to help elucidate the role of the opportunistic marine bacterial pathogen Vibrio coralliilyticus in stony coral tissue loss disease (SCTLD)

Mon 26 October 2020

The mAbDx Vibriosis RapidTest was used to help demonstrate that Vibrio coralliilyticus may be causing coinfections that exacerbate existing SCTLD lesions, and therefore may contribute to intraspecific differences observed between colonies. The study shows the potential of the Vibriosis RapidTest as a diagnostic tool capable of tracking the pathogen involved …
read more

Page 1 / 6 » ⇉

mAbDx | Immunodiagnostics

Other articles

Novel monoclonal antibodies that recognize mtDNA-encoded OXPHOS proteins have been developed by mAbDx and used in an Imaging Mass Cytometry (IMC) study of Parkinson’s disease.

Oregon Innovation Fund SBIR Matching Grant awarded to mAbDx

mAbDx, Inc. Awarded SBIR Phase I Grant

The mAbDx Vibriosis RapidTest has been used to help elucidate the role of the opportunistic marine bacterial pathogen Vibrio coralliilyticus in stony coral tissue loss disease (SCTLD)